New Treatment Option for Platinum-Resistant Ovarian Cancer – ENGOT
ENGOT shared a post on LinkedIn:
“Clinical trial update: Positive results from ENGOT-ov72/MITO/GOG-3073/ROSELLA, new Treatment Option on the Horizon for Platinum-Resistant Ovarian Cancer.
Both Dr. Domenica Lorusso, Director of the Gynecological Oncology Unit at Humanitas Hospital San Pio X in Milan and Dr. Alexander Olawaiye, Director of Gynecological Cancer Research at Magee-Women’s Hospital of the University of Pittsburgh, cooperated as Principal Investigators of the study.
As Dr. Domenica Lorusso explains below, the ROSELLA study results demonstrate that relacorilant in combination with nab-paclitaxel has the potential to become a key strategy to help improve patient outcomes.
Learn more about ENGOT-ov72/MITO/GOG-3073/ROSELLA from the official press release.”
More posts featuring ENGOT.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023